Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep learning-powered quantification of endocrine cells and CD3<sup>+</sup> T cells in the natural history of type 1 diabetes.

Diabetologia·2026
Same author

Autosomal Dominant Tubulointerstitial Kidney Disease Clinical Trial Simulator: Case Reports of Model-Informed Drug Development.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Addition of Clofazimine Enhances the Activity of Standard Treatment Regimen in a Mouse Model of Tuberculous Meningitis.

The Journal of infectious diseases·2026
Same author

Beyond Rifampin: Evaluating Rifapentine and Rifabutin as Alternative Treatments for TB Meningitis.

The Journal of infectious diseases·2026
Same author

Identifying optimal combination regimens for therapy of Mycobacterium tuberculosis with an algorithmic approach: prospective predictions and validations.

PloS one·2026

Related Experiment Video

Updated: Nov 30, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.0K

The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens.

G L Drusano1, Sarah Kim2, Mohammed Almoslem2,3

  • 1Institute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA gdrusano@ufl.edu.

Antimicrobial Agents and Chemotherapy
|November 17, 2020
PubMed
Summary

Identifying optimal drug combinations for tuberculosis is crucial due to resistance. The combination of pretomanid and moxifloxacin showed the greatest bacterial decline across different growth phases, suggesting its potential for effective tuberculosis treatment.

Keywords:
Greco modelMycobacterium tuberculosiscombination therapymetabolic state

More Related Videos

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.3K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.5K

Related Experiment Videos

Last Updated: Nov 30, 2025

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
05:29

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

3.0K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.3K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.5K

Area of Science:

  • Microbiology
  • Pharmacology
  • Infectious Diseases

Background:

  • Drug discovery for *Mycobacterium tuberculosis* has yielded new agents, but single-drug therapy is insufficient due to resistance.
  • Optimal combination regimens are needed for late-stage tuberculosis, but evaluating all potential combinations is resource-intensive.

Purpose of the Study:

  • To develop a screening procedure to identify promising drug combinations for tuberculosis with a high likelihood of reducing bacterial burden.
  • To evaluate the efficacy of different drug combinations against *Mycobacterium tuberculosis* in various growth phases.

Main Methods:

  • The Greco interaction model was used to examine pretomanid, moxifloxacin, linezolid, and bedaquiline in log-phase, acid-phase, and nonreplicative persister (NRP) growth.
  • Bacterial burden decline was used as the primary metric to rank combination regimens, with no correlation found between the interaction term α and bacterial kill.

Main Results:

  • The combination of pretomanid plus moxifloxacin demonstrated the largest bacterial burden decline in log and acid phases and was the second-best in the NRP phase.
  • Bedaquiline also showed significant bacterial kill, indicating its potential in combination therapies.
  • The screening process effectively identified combinations with high potential for bacterial reduction.

Conclusions:

  • A novel screening process prioritizing bacterial kill can identify optimal drug combinations for tuberculosis treatment.
  • The pretomanid plus moxifloxacin combination is a strong candidate for further evaluation in preclinical models.
  • This approach may expedite the identification of effective multi-drug regimens against *Mycobacterium tuberculosis*.